Immunome says FDA clears IND for IM-1340 solid-tumor ADC

The clinical-stage oncology company said the FDA cleared its IND application for IM-1340, a potential first-in-class antibody-drug conjugate for advanced solid tumors. Immunome expects to start a Phase 1 study in the fourth quarter of 2026.